%0 Journal Article %T Therapeutic Benefit of Placentrex in the Management of Acute Chemo Radiation Induced Mucositis in Oral Cancer Patients %J Asian Pacific Journal of Cancer Prevention %I West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. %Z 1513-7368 %A Kondaveeti, Satish Srinivas %A C V, Divyambika %A John, Christopher %A M, Manickavasagam %A S, Rajendiran %D 2018 %\ 11/01/2018 %V 19 %N 11 %P 3099-3103 %! Therapeutic Benefit of Placentrex in the Management of Acute Chemo Radiation Induced Mucositis in Oral Cancer Patients %K Chemoradiation %K Dysphagia %K Mucositis %K Placentrex %K head and neck cancer %R 10.31557/APJCP.2018.19.11.3099 %X Background: A troublesome and usually unavoidable consequence of Head and Neck chemo radiation is oralmucositis which decreases patients’ compliance and negatively influences the outcome of therapy by increasing overalltreatment time. Currently, no single effective recommended treatment exists for this problem and a variety of supportivecare measures have been practiced with limited benefits. This study was done to evaluate the therapeutic benefit ofPlacentrex in the management of oral mucositis seen in oral cancer patients undergoing treatment with concurrentchemoradiation. Methodology: This study was carried out, as a retrospective analysis, on oral cancer patients undergoingconcurrent chemoradiation with weekly Cisplatin regimen treated between Oct 2015 and July 2017. All the patientsreceived 2ml of Inj Placentrex, once daily administered intramuscularly for 4 weeks, NSAIDs, topical analgesics,and mouth wash as treatment for oral mucositis. The results were compared with a historical control group of 40 oralcancer patients who had received treatment prior to the study period without receiving Inj Placentrex as a part of oralmucositis management. Results: Over 60% of the patients in both groups were older than 60 years of age. Buccalmucosa was the predominant sub site of the investigated cancer type. The addition of placentrex resulted in delay inthe progression of mucositis, reduction of treatment breaks, regression of pain, and improvement of dysphagia whileleading to no adverse effects (p<0.05). Conclusion: Placentrex appears to be a beneficial therapeutic option for themanagement of concurrent chemo-radiation induced acute oral mucositis in oral cancer patients. %U https://journal.waocp.org/article_76628_c8e18aec2657ded0bbaf0678e4dc93c9.pdf